Newsletter | April 30, 2020

04.30.20 -- Biosimilars In An Election Year: What To Expect

Featured Editorial
Industry Insights
Is Your Sterile Injectable Ready For Changes In Raw Materials?

Over the life of a drug changes in raw materials are inevitable. But even a small modification can throw your drug out of compliance. Learn how to safeguard drug integrity when raw materials change.

Collaborative Project To Accelerate Downstream Biosimilar Processes

This case study demonstrates the optimization of the downstream purification process to improve product purity and recovery of the biosimilar Fc-fusion protein.

News Headlines